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Basal forebrain volume reliably predicts the
cortical spread of Alzheimer’s degeneration
Sara Fernández-Cabello,1,2 Martin Kronbichler,1,2,3 Koene R.A. Van Dijk,4
James A. Goodman,4 R. Nathan Spreng 5,6,7,8 and Taylor W. Schmitz9,10 on behalf of the
Alzheimer’s Disease Neuroimaging Initiative
Data used in preparation of this article were obtained from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database
(adni.loni.usc.edu). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or
provided data but did not participate in analysis or writing of this report. A complete listing of ADNI investigators can be found at:
http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf
Alzheimer’s disease neurodegeneration is thought to spread across anatomically and functionally connected brain regions.
However, the precise sequence of spread remains ambiguous. The prevailing model used to guide in vivo human neuroimaging
and non-human animal research assumes that Alzheimer’s degeneration starts in the entorhinal cortices, before spreading to the
temporoparietal cortex. Challenging this model, we previously provided evidence that in vivo markers of neurodegeneration within
the nucleus basalis of Meynert (NbM), a subregion of the basal forebrain heavily populated by cortically projecting cholinergic
neurons, precedes and predicts entorhinal degeneration. There have been few systematic attempts at directly comparing staging
models using in vivo longitudinal biomarker data, and none to our knowledge testing if comparative evidence generalizes across
independent samples. Here we addressed the sequence of pathological staging in Alzheimer’s disease using two independent
samples of the Alzheimer’s Disease Neuroimaging Initiative (n1 = 284; n2 = 553) with harmonized CSF assays of amyloid-b and
hyperphosphorylated tau (pTau), and longitudinal structural MRI data over 2 years. We derived measures of grey matter degen-
eration in a priori NbM and the entorhinal cortical regions of interest. To examine the spreading of degeneration, we used a
predictive modelling strategy that tests whether baseline grey matter volume in a seed region accounts for longitudinal change in a
target region. We demonstrated that predictive spread favoured the NbM!entorhinal over the entorhinal!NbM model. This
evidence generalized across the independent samples. We also showed that CSF concentrations of pTau/amyloid-b moderated the
observed predictive relationship, consistent with evidence in rodent models of an underlying trans-synaptic mechanism of patho-
physiological spread. The moderating effect of CSF was robust to additional factors, including clinical diagnosis. We then applied
our predictive modelling strategy to an exploratory whole-brain voxel-wise analysis to examine the spatial specificity of the
NbM!entorhinal model. We found that smaller baseline NbM volumes predicted greater degeneration in localized regions of
the entorhinal and perirhinal cortices. By contrast, smaller baseline entorhinal volumes predicted degeneration in the medial
temporal cortex, recapitulating a prior influential staging model. Our findings suggest that degeneration of the basal forebrain
cholinergic projection system is a robust and reliable upstream event of entorhinal and neocortical degeneration, calling into
question a prevailing view of Alzheimer’s disease pathogenesis.
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Introduction
Alzheimer’s disease neuropathology progresses in stages,
with certain brain regions affected by neuronal accumula-
tion of insoluble amyloid-b and hyperphosphorylated tau
(pTau) before others. The preferential accumulation of
amyloid-b and pTau in certain brain regions may reflect
the selective vulnerabilities of local neuronal populations
to these age-related ‘proteinopathies’ (Davies and
Maloney, 1976; Whitehouse et al., 1981; Arendt et al.,
1985, 2015; Mesulam et al., 2004; Mattson and Magnus,
2006; Geula et al., 2008; Braak and Del Tredici, 2011,
2015; Braak et al., 2011; Saxena and Caroni, 2011;
Baker-Nigh et al., 2015; Hanna Al-Shaikh et al., 2019),
which then spread to targets of the vulnerable population’s
projection system (Warren et al., 2013). Evidence in both
mouse models of Alzheimer’s disease (de Calignon et al.,
2012; Liu et al., 2012; Khan et al., 2014; Wu et al., 2016)
and in human Alzheimer’s disease patients (Grothe et al.,
2018; Sepulcre et al., 2018; Hanseeuw et al., 2019) indi-
cates that accumulated amyloid-b and pTau spreads across
anatomically and functionally connected brain regions over
time. Despite these observations, it remains ambiguous how
the accumulation of amyloid-b and pTau relates to the
spread of structural neurodegeneration across brain regions
over time (Harrison et al., 2019). This question can only be
resolved by integrating sensitive biomarkers of amyloid-b
and pTau with in vivo longitudinal measures of microstruc-
tural degeneration in both the subcortical and cortical brain
areas.
Post-mortem histology studies have linked abnormal
amyloid-b and pTau accumulation to early neurodegenera-
tion in the entorhinal cortex and in the nucleus basalis of
Meynert (NbM)—also referred to as Ch4/Ch4p (Mesulam
et al., 1983a, b; Mesulam and Geula, 1988)—the largest of
the cholinergic cell clusters constituting the basal forebrain
(Davies and Maloney, 1976; Whitehouse et al., 1981;
Arendt et al., 1985, 2015; Mesulam et al., 2004; Geula
et al., 2008; Baker-Nigh et al., 2015; Braak and Del
Tredici, 2015; Hanna Al-Shaikh et al., 2019). The selective
vulnerability of neurons in the entorhinal cortex and NbM
to these proteinopathies is attributed to their enormous size
and complexity of their axonal projections, and the high
propensity for sustained plasticity in these projections in
adulthood (Mesulam, 1999; Mattson and Magnus, 2006;
Saxena and Caroni, 2011; Wu et al., 2014; Roussarie et al.,
2019). One individual spiny stellate neuron in layer II of
the entorhinal cortex innervates the entire transverse axis of
the dentate gyrus, CA2/CA3 and the subiculum (Tamamaki
and Nojyo, 1993). Cholinergic neurons also have extremely
long and complex branching with the full arborization
length of a single neuron estimated in humans to be
4100 m (Wu et al., 2014). Unlike age-resilient neurons
in the primary sensory cortices, both entorhinal cortex
layer II glutamatergic neurons and NbM cholinergic neu-
rons must continually remodel their axonal arborizations
and synapses throughout the adult lifespan due to their
central role in attention and memory (Sarter et al., 2003;
Hasselmo, 2006; Botly and De Rosa, 2009; Heys et al.,
2010; Gu and Yakel, 2011; Mitsushima et al., 2013;
Schmitz and Duncan, 2018).
Although since the 1970s human post-mortem histology
research has provided consistent evidence for a subcortical
phase of Alzheimer’s disease pathology that precedes and
predicts cortical degeneration (Davies and Maloney, 1976;
Whitehouse et al., 1981; Arendt et al., 1985, 2015;
Mesulam et al., 2004; Geula et al., 2008; Braak and Del
Tredici, 2011, 2015; Braak et al., 2011; Baker-Nigh et al.,
2015; Hanna Al-Shaikh et al., 2019), the prevailing
Alzheimer’s staging model used to guide in vivo neuroima-
ging research in both humans and rodents assumes an
entorhinal cortex origin. Structural MRI studies in
humans tend to focus on the progression of abnormal
grey matter loss in entorhinal cortex and hippocampal tar-
gets of its projections (de Toledo-Morrell et al., 2000,
2004; Dickerson et al., 2001; Du et al., 2001; Good
et al., 2002; Karas et al., 2004; Hirata et al., 2005;
Kloppel et al., 2008; Gerardin et al., 2009; Frisoni et al.,
2010; Sorensen et al., 2016; Hett et al., 2019). Yet these
studies frequently exclude subcortical regions such as the
NbM from analysis entirely. Similarly, cross-species trans-
lational research using mouse models of Alzheimer’s disease
tend to assume an entorhinal cortex origin. Examples in-
clude recent influential work showing that accumulated
amyloid pathology in entorhinal cortex neurons potentiates
hyperphosphorylation of tau proteins, which then spread
via trans-synaptic mechanisms to distal neocortical targets
of entorhinal cortex, including the medial temporal and
posterior parietal cortex (de Calignon et al., 2012; Liu
et al., 2012; Khan et al., 2014; Wu et al., 2016). The
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patterns of tau propagation in mice parallel patterns of
grey matter loss observed in human in vivo imaging studies,
proving an underlying molecular-level mechanism that
might drive neurodegenerative spreading dynamics in the
entorhinal cortex (EC)!Neocortical model (Fig. 1A).
Challenging the EC!Neocortical model, we have previ-
ously demonstrated that the magnitude of early longitudinal
grey matter loss in the NbM was larger than in the entorh-
inal cortex in cognitively normal older adult humans exhibit-
ing abnormal CSF biomarkers of amyloid-b accumulation
(Schmitz and Spreng, 2016). We also found that baseline
NbM volumes were predictive of future rates of longitudinal
structural degeneration in entorhinal cortex, raising the pos-
sibility that amyloid-b accumulation potentiates the spread
of pTau via the same trans-synaptic mechanisms proposed
previously in mouse models of Alzheimer’s disease (de
Calignon et al., 2012; Liu et al., 2012; Khan et al., 2014;
Wu et al., 2016). If true, the NbM!EC model would add a
crucial ‘upstream’ link to the EC!Neocortical predictive
pathological staging of Alzheimer’s disease. Under this
model, amyloid-b pathology in the ascending cholinergic
projections from NbM first ‘seed’ the entorhinal cortex
with pTau via trans-synaptic spread, thereby eventuating
the pattern of temporo-parietal neurodegeneration typically
attributed to the earliest stages of Alzheimer’s disease.
Support for the NbM!EC model would have major clinical
implications, motivating a shift towards preventative treat-
ment strategies aimed at relieving age-related pressures on
the cortical cholinergic projection system.
However, our prior evidence in support of the NbM!EC
neurodegenerative ‘spread’ model is provisional. Like most
predictive staging studies in humans, we only examined a
single large heterogeneous cohort of older adults. A stronger
test of this model requires a systematic replication using
identical multimodal analytical procedures, between two
large independent cohorts. Moreover, the molecular profile
of background proteinopathy will need to incorporate both
amyloid-b and pTau, as opposed to amyloid-b alone
(Schmitz and Spreng, 2016), in order to better match the
pathophysiological conditions that are hypothesized to
drive the initial trans-synaptic spreading of pTau across
interconnected brain regions. Finally, a test of the
EC!Neocortical model is needed within this same study
to determine if neocortical ‘targets’ predicted by entorhinal
cortex neurodegeneration are similar to neocortical targets
predicted by entorhinal cortex trans-synaptic spreading (de
Calignon et al., 2012; Liu et al., 2012; Khan et al., 2014;
Wu et al., 2016). This would provide an important valid-
ation that our non-invasive in vivo analyses index a
common pathophysiological mechanism to those observed
in rodent models.
Here we directly compared the NbM!EC and
EC!NbM models of predictive pathological staging in a
large sample of older adults ranging from cognitively
normal to Alzheimer’s dementia, and then examined if
the results generalized to a second independent sample of
adults spanning the same clinical diagnostic continuum. In
each sample, we first integrated CSF biomarkers of amyl-
oid-b and pTau neuropathology into a ratio of pTau/amyl-
oid-b and delineated two groups of older adults in each of
the two samples using an independently defined cut-off
point that was recently cross-validated for the ratio of
pTau/amyloid-b (Hansson et al., 2018; Schindler et al.,
2018). Individuals below the cut-off point exhibit a ‘neu-
rotypical’ pTau/amyloid-b phenotype of brain ageing; indi-
viduals above the cut-off point exhibit an ‘Alzheimer’s
pathological’ pTau/amyloid-b phenotype. Because CSF
pTau/amyloid-b is sensitive to the earliest abnormalities
of Alzheimer’s disease (Jack et al., 2013), we identified
many cognitively normal adults falling above the cut-off
Figure 1 Proposed basal forebrain!entorhinal!neocortical model and regions of interest. (A) Predictive pathological staging
model of tau pathology originating in entorhinal cortex (EC) and spreading via trans-synaptic mechanism to cortical targets of its projection
system (black squares) updated to incorporate the basal forebrain degeneration as an ‘upstream’ event in the pathological cascade (purple square).
(B) Regions of interest of the NbM (purple) and the entorhinal cortex (blue) are superimposed on a coronal slice of the population DARTEL
template. (A) is adapted with permission from Liu et al. (2012).
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point in both samples. The Alzheimer’s pathological pTau/
amyloid-b phenotype therefore captures ‘pre-symptomatic’
individuals, in addition to mild cognitive impairment (MCI)
and Alzheimer’s disease individuals. In each sample, we
then tracked the two CSF groups with structural MRI in-
dices of baseline grey matter volume and longitudinal neu-
rodegeneration over a 2-year period. Both the CSF and
structural MRI data were acquired from multiple phases
of the Alzheimer’s Disease Neuroimaging Initiative (ADNI).
To examine the ‘spread’ of degeneration between NbM
and entorhinal cortex, we used a predictive modelling strat-
egy which tests whether baseline grey matter volume in a
seed region accounts for variation in subsequent longitu-
dinal degeneration (change over future time points) in a
target region. We determined whether evidence of predict-
ive pathological spread favoured either the NbM!EC or
EC!NbM model. We then determined whether CSF con-
centrations of pTau/amyloid-b moderated the observed
predictive relationship, consistent with an underlying
trans-synaptic mechanism of pathophysiological spread.
Additional moderating factors, including clinical diagnosis,
were evaluated in this framework. We then examined the
selectivity of predictive pathological spread between NbM
and entorhinal cortex using a whole-brain voxel-wise pre-
dictive modelling strategy. Finally, we used the same whole-
brain strategy to test whether the EC!Neocortical model
recapitulates the spread of neuropathology from entorhinal
cortex to temporoparietal cortices observed in prior cross-
species translational work (de Calignon et al., 2012; Liu
et al., 2012; Khan et al., 2014; Wu et al., 2016). If degen-
eration in the basal forebrain cholinergic projection system
is a robust and reliable upstream event of entorhinal de-
generation, then it should predict localized entorhinal de-
generation, whereas entorhinal cortex should predict
downstream events in temporal and parietal cortices.
Materials and methods
ADNI data
Data used in the preparation of this article were obtained from
the Alzheimer’s Disease Neuroimaging Initiative (ADNI) data-
base (adni.loni.usc.edu). The ADNI was launched in 2003 as a
public-private partnership, led by principal investigator
Michael W. Weiner, MD (Mueller et al., 2005). The primary
goal of ADNI has been to test whether serial MRI, PET, other
biological markers, and clinical and neuropsychological assess-
ment can be combined to measure the progression of MCI and
early Alzheimer’s disease.
We used data from the ADNI-1 as the first cohort and the
combined data from ADNI-GO and ADNI-2 (ADNI-GO/2) as
the second cohort. ADNI-1 was carried out in 1.5 T magnetic
resonance scanners and ADNI-GO/2 in 3 T magnetic resonance
scanners. All high-resolution T1 structural MRI scans were
downloaded from ADNI LONI (http://adni.loni.usc.edu/). A
total of 502 ADNI-1 structural MRI scans were downloaded
from a standardized 2-year interval image collection. This data
collection was created to minimize variability between studies
and ensure a minimum quality control of the images (Wyman
et al., 2013). To obtain the ADNI-GO/2 structural MRI scans,
we first selected those subjects who had CSF biomarker data
(see below) and searched by their research IDs (RIDs). We
downloaded longitudinal structural MRI images from 714
ADNI-GO/2 participants. To select the two longitudinal time
points for each individual, we applied a bounded interval of a
mean = 1.5 years  12 months to maximize the inclusion of
participants. One hundred and four participants did not have
longitudinal structural MRI data within the bounded interval.
For ADNI sites with GE and Siemens scanners, we used images
corrected for distortions (GradWarp) and B1 non-uniformity.
For ADNI sites with Philips scanners, these corrections are
applied at acquisition (see http://adni.loni.usc.edu/methods/mri-
tool/mri-pre-processing/). Finally, to be able to compare ADNI-1
and ADNI-GO/2 data as two independent samples, we dis-
carded participants from ADNI-GO/2 who also took part in
the ADNI-1 studies (n = 49), due to the smaller sample size of
the ADNI-1 cohort.
CSF biomarkers
Accumulation of brain amyloid-b in plaques and pTau in
neurofibrillary tangles are the main proteinopathies associated
with Alzheimer’s disease (Shaw et al., 2009; Hansson et al.,
2018; Schindler et al., 2018). CSF samples of amyloid-b and
pTau from the baseline visit were produced with a fully
automated Elecsys protocol (Supplementary material). We
calculated a ratio of pTau/amyloid-b and used a standardized
cut-off of 0.028, which was recently cross-validated between
the ADNI and Swedish BioFinder studies (Hansson et al.,
2018) to classify participants into abnormal (pTau/amyloid-
b5 0.028) and normal (pTau/amyloid-b50.028) CSF
groups. Using ratios of pTau/amyloid-b supersedes using
single analytes to distinguish amyloid status using PET
(Schindler et al., 2018). Moreover, in the ADNI dataset, a
high concordance was found between this CSF pTau/amyl-
oid-b cut-off point and amyloid PET cut-off points (Hansson
et al., 2018). Two hundred and sixteen participants from
ADNI-1 did not have CSF measures and were therefore not
included. It is important to note that our grouping strategy is
purely based on CSF biomarkers, independent of any cognitive
or clinical diagnosis, though we follow-up with analyses of
clinical diagnosis (refer to the ‘Results’ section).
APOE genotyping
The e4 allele of the APOE gene is the strongest genetic risk
factor for non-familial Alzheimer’s disease (Corder et al.,
1993; Strittmatter et al., 1993; Farrer et al., 1997) and is
thought to interact with the selective vulnerability of choliner-
gic basal forebrain neurons by disrupting the capacity of these
cells to support and maintain their enormous axonal mem-
branes (Wurtman et al., 1990; Nitsch et al., 1992; Wurtman,
1992; Poirier et al., 1993, 1995; Poirier, 1994). To study the
effect of the CSF Alzheimer’s disease biomarkers independently
of other factors, we included the APOE genotype as a covari-
ate of no interest in our analyses. The APOE information for
all individuals with both structural MRI and CSF data was
obtained from the APOERES.csv spreadsheet and the e4 +
status was defined as having at least one e4 allele. A blood
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sample at the screening or baseline visit was collected for
APOE genotyping and genotype analysis was performed fol-
lowing standard procedures (Saykin et al., 2010).
Neuropsychological assessment
Cognitive performance was assessed with a neuropsychological
battery that covered a wide range of cognitive functions,
including short and long-term memory, language, executive
function and attention. We used baseline data from two com-
posite scores, one for memory and one for executive function,
derived from the ADNI neuropsychological battery that were
recently validated using confirmatory factor analysis (Crane
et al., 2012; Gibbons et al., 2012). Specifically, the memory
score integrated the Mini-Mental State Examination (MMSE),
Rey Auditory Verbal Learning Test, Alzheimer’s Disease
Assessment Scale, and Logical Memory tests. The executive
function score integrated the Category Fluency, Digit Span
Backwards, Digit Symbol Substitution, Trails A and B and
Clock Drawing tests. In addition to the memory and executive
function factors, we present the Boston Naming and the Clock
Drawing tests and the six subcategories of the Clinical
Dementia Rating (CDR) Scale to provide a more comprehen-
sive evaluation of the cognitive and functional profiles of the
participants. The CDR subtests include the domains of
Memory, Orientation, Judgement and Problem Solving,
Community Affairs, Home and Hobbies and Personal Care.
ADNI clinical diagnosis
At the baseline visit, an initial diagnosis recommended by the
ADNI Clinical Core was used to classify participants into cog-
nitively normal (CDR = 0, MMSE 24–30), mild cognitively
impaired (CDR = 0.5, MMSE 24–30, with memory impair-
ments but largely preserved general cognition and functional
capacity) and Alzheimer’s disease (CDR 0.5–1, MMSE 20–26,
with memory impairments but largely impaired general cogni-
tion and functional capacity). These diagnostic classifications
are based on standard cognitive and functional measures typ-
ical of clinical trials (Aisen et al., 2010, 2015; Petersen et al.,
2010). More details on the inclusion and diagnostic criteria
can be found at http://adni.loni.usc.edu/.
CSF groups by neuropsychological
status
To confirm that our CSF grouping strategy differentiated par-
ticipants based on measures of neuropsychological status, we
collapsed the baseline neuropsychological data from both
ADNI cohorts to compare the abnormal and normal CSF
groups on the MMSE, a common test of general cognitive
function, in the two composite scores of memory and executive
function as well as in the Boston Naming Test, Clock Drawing
Test and in the CDR subcategories (see preceding section). For
each test, we computed one-way fixed effect ANOVAs with
CSF group (abnormal CSF, normal CSF) as a factor, covarying
for age, sex, education, cohort and APOE genotype. These
models revealed significant main effects of CSF pathology on
cognition in all tests. Consistent with the sensitivity of CSF
pTau/amyloid-b to pathological ageing, the abnormal CSF
group exhibited significantly more cognitive impairment than
the normal CSF group in all the tests (Table 1).
Longitudinal structural MRI
A serial longitudinal pipeline scheme in SPM12 r7219 (https://
www.fil.ion.ucl.ac.uk/spm/) implemented in MATLAB 2013a
was used to calculate the grey matter volume changes from
the structural MRI data (Ashburner and Ridgway, 2012).
This procedure unifies rigid-body registration, intensity in-
homogeneity correction and non-linear diffeomorphic trans-
formation in a single iterative model. Initially, all of the
individual time points were co-registered to the ICBM 152
volume to ensure good starting parameters for the high-dimen-
sional DARTEL warping algorithm. We then used within-sub-
ject symmetric diffeomorphic registration of the two time
points to create a midpoint average T1 image for each subject.
Computing a midpoint average image prevents introduction of
biases associated with using individual time points as the ref-
erence (e.g. results differ depending on the time point that is
used as a reference). The midpoint average was scaled by the
interscan interval. The registration step produced Jacobian de-
terminant maps, which index contractions and expansions for
each time point relative to the midpoint average image. The
default parameters for noise estimation, warping and bias
regularizations were used. The midpoint average images were
then segmented using the SPM12 tissue probability map with
the following settings: light regularization, 60 mm of full-width
at half-maximum (FWHM) Gaussian smoothness of bias and
2, 2, 2, 3, 4, 2 Gaussians per tissue type. The resulting 1.5
mm3 grey and white matter maps were used to create separate
DARTEL group templates for each sample (ADNI-1 and
ADNI-GO/2). The DARTEL algorithm improves the intersub-
ject alignment by using multiple parameters per voxel when
aligning the images (Ashburner, 2007). The segmented grey
matter maps were multiplied by the Jacobian determinants of
each time point (Mechelli et al., 2005). We then warped the
segmented grey and white matter maps into the DARTEL tem-
plate space with the ‘preserve amount’ option. Default settings
were used elsewhere. The warping step produced modulated
grey and white matter volumetric maps for each time point.
To check the quality of the images for subsequent analyses,
the warped, modulated grey matter maps of each time point
were visually inspected for segmentation and normalization
inaccuracies by creating a plot showing a slice for all the sub-
jects and were inspected for the presence of outliers by calcu-
lating the correlation between all the volumes using the
CAT12 toolbox (http://dbm.neuro.uni-jena.de/cat/). Subjects
who exhibited a correlation below 2 standard deviations
(SD) and abnormalities on their segmented grey matter
volume (e.g. low signal intensity, inhomogeneities, warping
errors) were excluded. Two subjects were discarded because
of low data quality in ADNI-1 and eight in ADNI-GO/2. See
Table 2 for complete information of the included participants.
Region of interest definition
To test the predictive pathological models between the NbM
and entorhinal cortex, we extracted grey matter volumes from
two regions of interest using probabilistic atlases. The NbM
and entorhinal cortex regions of interest were bilateral (com-
bined across hemispheres) and were created in MNI space with
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the SPM Anatomy Toolbox r 2.2b (http://www.fz-juelich.de/
inm/inm-1/DE/Forschung/) using previously published
probabilistic maps of the NbM (Zaborszky et al., 2008) and
the entorhinal cortex (Amunts et al., 2005) (Fig. 1B). The
NbM region of interest is equivalent to areas Ch4 and Ch4p
(Mesulam et al., 1983a, b; Mesulam and Geula, 1988). The
Ch4p area is also referred to as the nucleus subputaminalis of
Ayala and represents the rostrolateral extension of the NbM.
Research by others on the subregional degeneration within the
distributed nuclei of the basal forebrain has highlighted the
Ch4p region as particularly vulnerable to early degeneration
in amnestic MCI (Teipel et al., 2005, 2014; Grothe et al.,
2012; Kilimann et al., 2014). Because of their neuroanatomical
proximity to one another and higher susceptibility to
Alzheimer’s disease neurodegeneration, we have considered
the Ch4p and Ch4 regions as a single unit. The regions of
interest were thresholded at 50% probability (minimum over-
lap of 5/10 post-mortem brains). The regions of interest were
then resampled and warped to the DARTEL group template
(Fig. 1B). Estimates of modulated grey matter volume (in
units of ml) at each time point were obtained using the
region of interest as a masking region, and by summing the
total intensity of voxels falling within the masking region
adjusted for the size and number of voxels (http://www0.cs.
ucl.ac.uk/staff/g.ridgway/vbm/get_totals.m). No spatial smooth-
ing was applied to the volumes. In addition, the total grey
matter from the modulated and warped individual time
points was calculated using the same procedure. The total
intracranial volume (TICV) was computed by summing up
the tissue volumes of grey matter, white matter and CSF of
the segmented average images produced in a previous step
using the seg8.mat file from the segmentation (Malone
et al., 2015).
To assess longitudinal changes in grey matter volumes, the
annualized per cent change (APC) from baseline was calculated
using Equation 1 (Cavedo et al., 2017):
Table 1 Neuropsychological function at baseline by CSF group (collapsed across ADNI cohorts)
CSF group F P
Abnormal CSF Normal CSF
MMSE 26.28 (2.83) 28.65 (1.57) F(1,830) = 112.74 50.001\
Memory function –0.19 (0.81) 0.86 (0.68) F(1,829) = 243.77 50.001\
Executive function –0.20 (1.01) 0.72 (0.88) F(1,829) = 123.96 50.001\
BNT 25.28 (4.71) 27.48 (3.19) F(1,818) = 30.28 50.001\
Clock-Draw 3.98 (1.18) 4.57 (0.72) F(1,829) = 37.26 50.001\
CDR-MEM 0.64 (0.43) 0.19 (0.28) F(1,830) = 173.80 50.001\
CDR-ORIENT 0.43 (0.46) 0.06 (0.18) F(1,830) = 113.30 50.001\
CDR-JUDGE 0.45 (0.39) 0.11 (0.22) F(1,830) = 136.57 50.001\
CDR-COMMUN 0.32 (0.41) 0.05 (0.16) F(1,830) = 86.47 50.001\
CDR-HOME 0.37 (0.46) 0.07 (0.20) F(1,830) = 83.26 50.001\
CDR-CARE 0.09 (0.29) 0.01 (0.11) F(1,830) = 9.98 0.001\
Mean (SD) of the neuropsychological baseline performances. The abnormal CSF group exhibited worse general cognition (MMSE), memory, executive function, naming, visuospatial
functions and in all subtests of the Clinical Dementia Rating (CDR) scale compared to the normal CSF group. Total scores are reported for the Boston Naming and Clock Drawing
Tests. BNT = Boston Naming Test; CDR-CARE = CDR personal care domain; CDR-COMMUN = CDR community affairs domain; CDR-HOME = CDR home and hobbies domain;
CDR-JUDGE = CDR judgement and problem solving domain; CDR-MEM = CDR memory domain; CDR-ORIENT = CDR orientation domain; MMSE = Mini-Mental State
Examination.
\Significant after Bonferroni correction at P5 0.05 (n = 11 tests).
Table 2 Participant demographics, APOE genotype and CSF assays
ADNI-1 ADNI-GO/2
Abnormal CSF Normal CSF Test Abnormal CSF Normal CSF Test
n (total) 174 110 2 = 14.42\\\ 316 237 2 = 11.28\\\
CN/MCI/AD 28/89/57 64/41/5 2 = 64.26\\\ 39/130/147 162/75/0 2 = 230.84\\\
Age 74.51 (7.04) 75.53 (6.50) t = –1.24 72.16 (7.22) 70.44 (6.56) t = 2.91\\
Female/male 66/108 50/60 2 = 1.28 146/170 110/127 2 = 0.00
Education 15.57 (2.99) 15.88 (2.89) t = –0.87 15.96 (2.66) 16.62 (2.56) t = 2.96\\
e4 + /e4– 124/50 16/94 2 = 84.48\\\ 222/94 60/177 2 = 107.54\\\
Amyloid-b 579.28 (179.15) 1468.76 (554.28) t = –16.30\\\ 641.66 (192.73) 1376.54 (589.78) t = –18.45\\\
pTau 34.33 (12.33) 19.6 (6.45) t = 13.16\\\ 35.75 (14.98) 18.23 (6.52) t = 18.57\\\
Information of the included participants from the ADNI-1 and ADNI-GO/2 cohorts by CSF group. Values represent mean (SD) unless otherwise specified. Ab = CSF concentration
of the amyloid beta 1-42 peptide; pTau = CSF concentration of hyper phosphorylated tau (at threonine 181). Independent samples t-tests (t) and chi-square (2) tests were used to
test CSF group differences within each ADNI cohort. Baseline clinical diagnosis: AD = Alzheimer’s disease; CN = cognitively normal; MCI = mild cognitively impaired. APOE status:
e4 + = e4 carrier, e4– = e4 non-carrier. Age and education are in years. Amyloid-b1-42 and pTau concentrations are in pg/ml.
\\\P5 0.001, \\P5 0.005.
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To compare baseline volumes and longitudinal volume changes
between the CSF groups, we computed fixed effects ANOVAs
for each ADNI cohort and each region of interest with CSF
group (abnormal CSF, normal CSF) as a factor covarying for
age, sex, education, TICV, baseline total grey matter and
APOE genotype (see Supplementary Fig. 1 for the bivariate
correlation values among the modelled variables). We then
pooled the data from both ADNI cohorts and computed
one-way fixed effects ANOVAs with CSF group (abnormal
CSF, normal CSF) as a factor, correcting for the same covari-
ates, and an additional covariate for study cohort (Ma et al.,
2019). All ANOVA models were carried out in R with a type
III sums of squares.
Robust regression
To test the predictive staging models (NbM!EC and
EC!NbM), robust linear regression analyses were carried
out in Matlab R2018b with filtm and a bisquare weight func-
tion to minimize the influence of outliers. Each model covaried
for age, sex, education, TICV, baseline total grey matter and
APOE genotype. The predictive models were calculated first
for each dataset separately and then in the pooled sample
collapsing across both cohorts and including an additional
covariate for cohort. All data were z-scored before entering
the analysis.
Moderation analyses of independent samples
The moderation analyses (Fig. 3E and J) were carried out using
the PROCESS macro for SPSS (Hayes, 2017). The abnormal
and normal CSF groups served as the dichotomous moderator
variable in all models. Age, sex, education, TICV, baseline
total grey matter, APOE genotype and cohort were included
as covariates in all models. All data were mean centred. The
moderation analysis used a heteroscedasticity consistent stand-
ard error and covariance matrix estimator.
Comparison of correlations between dependent
samples
To compare correlation coefficients between the NbM!EC
and EC!NbM models, we used cocor to account for the de-
pendence between the two models (Diedenhofen and Musch,
2015).
Whole-brain analysis
Whole-brain APC maps were calculated with the previous
APC formula with the imcalc tool in SPM12. The APC
maps were smoothed with a 4 mm FWHM Gaussian kernel
(Grothe et al., 2012; Cavedo et al., 2017). For exploratory
purposes, we tested two whole-brain models. The first model
investigated the anatomical specificity of the relationship
between baseline NbM volumes and longitudinal
degeneration in the entorhinal cortex using whole-brain
voxel-wise analysis. The second model investigated the rela-
tionship between baseline EC volumes and longitudinal
degeneration in adjacent medial temporal cortices using
whole-brain voxel-wise analysis. Both models were evaluated
in the abnormal CSF group pooled across the ADNI-1 and
ADNI-GO/ADNI-2 datasets. These regression models were
estimated with non-parametric permutation testing using the
Statistical Non-Parametric Mapping toolbox v13 (http://war-
wick.ac.uk/snpm) for SPM12 (Nichols and Holmes, 2002).
Age, sex, education, TICV, baseline total grey matter,
APOE genotype and cohort were included as covariates.
The models were estimated with 5000 permutations, without
variance smoothing and global normalization, and including
an explicit mask of the binarized and thresholded (40.1)
DARTEL grey matter ADNI-GO/2 group template. Results
are presented with a voxel-level threshold of P5 0.05
family-wise error (FWE) corrected for multiple comparisons
across the brain.
Data availability
The data that support the findings of this study are openly
available for request in LONI https://ida.loni.usc.edu/login.jsp.
Results
Abnormal CSF pTau/amyloid-b
differentiates MRI indices of NbM and
entorhinal cortex neurodegeneration
We first examined whether the CSF pTau/amyloid-b group-
ing criteria differentiates patterns of baseline NbM and
entorhinal cortex volume. Consistent with a link between
CSF pTau/amyloid-b biomarkers of neuropathology and
neurodegeneration, we found that individuals with abnor-
mal CSF cut-offs had smaller baseline volumes in the NbM
in the ADNI-1 [main effect of CSF Group: F(1,276) = 9.04,
P = 0.002, 2 = 0.013], ADNI-GO/2 [main effect of CSF
Group: F(1,545) = 67.01, P5 0.001, 2 = 0.042] and in
the pooled data of both cohorts [main effect of CSF
Group: F(1,828) = 75.88, P5 0.001, 2 = 0.030;
Fig. 2A]. Baseline volumes of the entorhinal cortex were
also smaller in the abnormal CSF group in ADNI-1 [main
effect of CSF Group: F(1,276) = 8.71, P = 0.003,
2 = 0.012], ADNI-GO/2 [main effect of CSF Group:
F(1,545) = 14.19, P5 0.001, 2 = 0.008] and in the
pooled data [main effect of CSF Group: F(1,828) =
25.86, P5 0.001, 2 = 0.010; Fig. 2C].
We next examined if the CSF pTau/amyloid-b grouping
criteria also influenced longitudinal indices of APC in
the NbM and entorhinal cortex. These models revealed
that individuals with abnormal CSF biomarkers showed
more longitudinal atrophy in the NbM in the ADNI-
GO/2 [main effect of CSF Group: F(1,545) = 7.89,
P = 0.005, 2 = 0.014] and in the pooled dataset [main
effect of CSF Group: F(1,828) = 9.79, P = 0.002,






/brain/article/143/3/993/5811050 by guest on 03 February 2021
2 = 0.011], but not in ADNI-1 [main effect of CSF
Group: F(1,276) = 2.54, P = 0.11, 2 = 0.009; Fig. 2B].
In the entorhinal cortex, the abnormal CSF group ex-
hibited more longitudinal atrophy in ADNI-1 [main
effect of CSF Group: F(1,276) = 23.91, P5 0.001,
2 = 0.072], ADNI-GO/2 [main effect of CSF Group:
F(1,545) = 26.38, P5 0.001, 2 = 0.041] and in the
pooled data [main effect of CSF Group: F(1,828) =
47.51, P5 0.001, 2 = 0.048; Fig. 2D]. Finally, we inves-
tigated if the magnitude of longitudinal degeneration in
the NbM and in the entorhinal cortex differed between
individuals at different disease stages. To do so, we
cross-referenced the CSF groups with the ADNI baseline
clinical diagnosis (Schmitz and Spreng, 2016; Schmitz
et al., 2018) and found that individuals with abnormal
CSF biomarkers in all disease stages had increased degen-
eration in both the NbM and the entorhinal cortex.
Crucially, individuals in the preclinical disease stage (ab-
normal CSF and normal cognition at baseline) showed
greater magnitudes of degeneration in the NbM and the
entorhinal cortex compared to the cognitively normal con-
trols (normal CSF and normal cognition at baseline)
(Supplementary Fig. 2 and Supplementary Table 1).
Consistent with our hypotheses, CSF biomarkers of ab-
normal pTau/amyloid-b accumulation in the CNS differ-
entiated both smaller baseline grey matter volume and
larger magnitudes of longitudinal grey matter degener-
ation in the NbM and entorhinal cortex.
Abnormal pTau/amyloid-b
potentiates the predictive spread of
NbM!EC degeneration
Thus far, our multimodal CSF and structural MRI analyses
have treated patterns of neurodegeneration in the NbM
and entorhinal cortex separately. We next used regres-
sion-based modelling to test if the degeneration in the
NbM and in the entorhinal cortex reflects interdependent
pathological processes. If degeneration in the NbM pre-
cedes degeneration in the entorhinal cortex due to selective
neuronal vulnerability of cholinergic neurons inducing a
degenerative ‘spreading,’ then NbM baseline volumes
should predict degeneration in the entorhinal cortex
(NbM!EC). However, if degeneration in NbM and
entorhinal cortex occurs in parallel due to a common
global pathology, then baseline volumes of either region
should predict degeneration in the other. Alternatively, if
degeneration in NbM and entorhinal cortex reflects inde-
pendent local pathology, then baseline volumes of neither
region should predict degeneration in the other.
We used robust linear regression to examine these com-
peting models in the abnormal and normal CSF groups.
Consistent with an interdependent NbM!EC model, we
found in the abnormal CSF group that baseline NbM vol-
umes predicted longitudinal degeneration in the entorhinal
cortex in both ADNI-1 [r = 0.20, t(166) = 2.12, P = 0.03,
confidence interval (CI): 0.01 to 0.38; Fig. 3A] and ADNI-
Figure 2 Abnormal pTau/amyloid-b differentiates NbM and entorhinal cortex indices of structural degeneration. Violin plots
showing the means and standard errors of the baseline and longitudinal changes of the NbM (purple bars) and entorhinal cortex (EC, blue bars) a
priori regions of interest in the two independent datasets (ADNI-1 and ADNI-GO/2) and the pooled data of both datasets. Baseline NbM (A) and
entorhinal cortex (C) volumes were smaller in the abnormal CSF (aCSF) group. Longitudinal degeneration in the NbM (B) and in the entorhinal
cortex (D) was larger in the abnormal CSF group. BL = baseline volume. P5 0.001; P5 0.01; P5 0.05. Horizontal lines are the median,
boxes are interquartile range and vertical lines are 1.5 the interquartile range.
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GO/2 [r = 0.37, t(308) = 5.15, P50.001, CI: 0.22 to
0.51; Fig. 3B]. We next examined whether the predictive
pathological staging of NbM and entorhinal cortex degen-
eration is observable under conditions of normal CSF
pTau/amyloid-b. It could be the case that the underlying
neuropathological process driving this relationship also
occurs at ‘neurotypical’ levels of pTau/amyloid-b, but
that this process is exacerbated in the abnormal CSF
group. In this case, we would expect to observe the
same NbM!EC interrelationship, though possibly at a
smaller magnitude. We found negligible evidence for the
NbM!EC model in the normal CSF group in ADNI-1 [r
= –0.17, t(102) = –1.14, P = 0.25, CI: –0.46 to 0.12;
Fig. 3C]. However, we did observe a predictive relation-
ship in ADNI-GO/2 [r = 0.21, t(229) = 2.47, P = 0.01, CI:
0.04 to 0.39; Fig. 3D]. We then examined these relation-
ships in the pooled data. The results supported the
NbM!EC model in the abnormal CSF [r = 0.30, t(481)
= 5.32, P50.001, CI: 0.19 to 0.41] but not the normal
CSF group [r = 0.11, t(338) = 1.45, P = 0.14, CI: –0.04 to
0.26] (Fig. 3E and Supplementary Table 2). To exclude
the possibility that the results were distorted by possible
collinearities among the model predictors and covariates,
we computed each model without any of the covariates.
The exclusion of covariates did not alter any of the above
findings (Supplementary Table 3). To directly test if the
relationship observed in the pooled abnormal CSF group
was significantly different from that observed in the
pooled normal CSF group, we computed a moderation
analysis with CSF group (abnormal, normal) as a dichot-
omous moderator on the NbM!EC interrelationship
(refer to the ‘Materials and methods’ section). We found
a significant moderating effect of CSF group on the
NbM!EC interrelationship [t(826) = 2.55, P = 0.01],
indicating a more pronounced interregional spread in the
abnormal CSF compared to the normal CSF group.
We next tested the competing model of EC!NbM pre-
dictive pathological spread, focusing first on the abnormal
CSF group. We found that entorhinal cortex baseline vol-
umes did not predict longitudinal decreases in the NbM in
ADNI-1 [r = –0.06, t(166) = –0.56, P = 0.57, CI: –0.29 to
0.16; Fig. 3F], in ADNI-GO/2 [r = 0.10, t(308) = 1.18,
P = 0.23, CI: –0.06 to 0.27; Fig. 3G] or in the pooled
sample [r = 0.02, t(481) = 0.26, P = 0.79, CI: –0.11 to
0.14; Fig. 3J] (Supplementary Table 2). Moreover, we
found negligible evidence for the EC!NbM model in the
normal CSF group in ADNI-1 [r = 0.12, t(102) = 0.92,
P = 0.36, CI: –0.14 to 0.38; Fig. 3H], ADNI-GO/2
[r = 0.18, t(229) = 1.72, P = 0.08, CI: –0.03 to 0.40;
Fig. 3I], or in the pooled sample [r = 0.12, t(334) = 1.53,
Figure 3 Predictive pathological staging models. In the abnormal CSF group (aCSF), smaller baseline NbM volumes (x-axis: negative z-
score values) were associated with greater magnitudes of longitudinal degeneration in the entorhinal cortex (y-axis: negative z-score values for T2
– T1 APC) in both (A) ADNI-1 and (B) ADNI-GO/2 (lower left corner of the graphs). No such relationships were observed in the normal CSF
(nCSF) groups in (C) ADNI-1 but it was present in (D) ADNI-GO/2. (E) CSF concentrations of pTau/amyloid-b (normal CSF versus abnormal
CSF) significantly moderated the relationship between baseline NbM volume and longitudinal entorhinal cortex degeneration. (F–J) Baseline
entorhinal cortex volumes did not predict longitudinal degeneration in the NbM in either the abnormal or normal CSF, in either ADNI-1 or
ADNI-GO/2. nor did it moderate this relationship. BL = baseline volume. P5 0.001; P5 0.01; P5 0.05.
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P = 0.12, CI: –0.03 to 0.27; Fig. 3J] (Supplementary Table
2). Nor was there a significant interaction between CSF
group and the relationship between entorhinal cortex and
NbM in the pooled sample [t(826) = 1, P = 0.62; Fig. 3J].
We then directly compared the two predictive staging
models, NbM!EC and EC!NbM, using a slopes analysis
between dependent samples. We found that the coefficients
in each model were significantly different from one another
in the abnormal CSF group [z = 5.54; P5 0.001; 95% r
CI: 0.1831 to 0.3847] but not in the normal CSF group
(z = 0.08; P = 0.931; 95% r CI: –0.1424 to 0.13) (Fig. 4).
Taken together, our predictive pathological models sug-
gest that neurodegeneration of the cholinergic basal fore-
brain system may occur in both the abnormal and normal
CSF ageing phenotypes, but that abnormal proteopathic
pTau/amyloid-b accumulation greatly exacerbates this
effect. The results also demonstrate that the EC!NbM
model does not fit a neurobiologically plausible predictive
staging of neurodegeneration in either the abnormal or
normal CSF cohort.
Clinical diagnosis does not moderate
the relationship between NbM!EC
Having demonstrated that the NbM!EC relationship was
more prominent and reliable in the abnormal CSF group,
we then investigated whether the severity of the disease had
an impact on the strength of this relationship in the pooled
abnormal CSF group. We predicted that the MCI abnormal
CSF subgroup would exhibit the strongest pattern of de-
generative ‘spreading’ between NbM and entorhinal cortex,
followed by cognitively normal abnormal CSF and
Alzheimer’s disease abnormal CSF subgroups (Schmitz
and Spreng, 2016). Although MCI abnormal CSF individ-
uals exhibited a steeper positive slope compared to the
other two diagnostic groups, clinical diagnosis was not a
significant moderating effect (Supplementary Fig. 3)
[t(1,479) = 1.65, P = 0.49], indicating that the predictive
relationship was robust across clinical diagnostic subgroups
of the abnormal CSF cohort.
NbM!EC predictive pathological
spreading is anatomically specific
How spatially selective is the observed interrelationship be-
tween NbM and entorhinal cortex in the abnormal CSF
group? To determine where degeneration is predicted
based on NbM integrity, we performed a voxel-wise regres-
sion analysis between baseline volumes in the NbM and
longitudinal APC in every brain voxel. The model collapsed
abnormal CSF individuals across the two ADNI Cohorts
into a single ‘Pooled’ cohort. After FWE correction for
multiple comparisons, we found that baseline NbM vol-
umes predicted degeneration in a circumscribed cluster of
regions localized to the right entorhinal and perirhinal cor-
tices and in the left middle temporal gyrus (Fig. 5A). The
predictive pathological spread of NbM!EC
Figure 4 Amyloid-b and pTau potentiate the spread of neurodegeneration from NbM to entorhinal cortex. The slopes of the
NbM!EC and EC!NbM robust regression models were different in (A) the pooled abnormal CSF group (aCSF), but (B) not in the pooled
normal CSF group. The x-axes reflect baseline NbM volumes (purple lines) and baseline entorhinal cortex volumes (blue lines). The y-axes reflect
APC in the entorhinal cortex (purple lines) and in the NbM (blue lines). Baseline volumes and APC units were z-scored (z). BL = baseline volume;
nCSF = normal CSF group. P5 0.001; P5 0.01; P5 0.05.
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neurodegeneration therefore exhibits a high degree of ana-
tomical specificity.
In our a priori region of interest-based regression models,
we found negligible evidence in support of the EC!NbM
model. However, following from non-human animal work
(de Calignon et al., 2012; Liu et al., 2012; Khan et al.,
2014; Wu et al., 2016), we hypothesized that predictive
spread of degeneration from entorhinal cortex might
target anatomically and functionally connected cortical
areas including the parahippocampal and posterior parietal
cortices. To test this hypothesis, we computed a second
voxel-wise regression analysis in the pooled abnormal
CSF group between baseline volumes in the entorhinal
cortex and longitudinal APC in every brain voxel of the
grey matter mask (refer to the ‘Materials and methods’
section). After FWE correction, we found that baseline
entorhinal cortex volumes predicted longitudinal degener-
ation in a circumscribed network of temporal cortical re-
gions including the entorhinal, perirhinal, parahippocampal
and fusiform cortices and temporal poles (Fig. 5B).
Additional clusters were detected in the insular and poster-
ior parietal cortices.
Finally, we tested the same models in the normal CSF
cohort, collapsing individuals from both ADNI cohorts.
No significant voxels were found at the corrected statistical
threshold (P5 0.05 FWE) in either of the models
(NbM!whole brain; EC!whole brain). Taken together,
the voxel-wise regression results show that among individ-
uals expressing abnormal CSF: (i) baseline NbM volumes
selectively predict degeneration in the entorhinal cortex and
adjacent perirhinal cortex; and (ii) entorhinal cortex degen-
eration ‘spreads’ to anatomically and functionally con-
nected areas including the parahippocampal gyrus and
other temporoparietal regions (de Calignon et al., 2012;
Liu et al., 2012; Khan et al., 2014; Wu et al., 2016).
Discussion
We provide evidence that degeneration in the NbM is an
upstream event of subsequent degeneration in the entorh-
inal cortex and adjacent medial temporal cortices. Our re-
sults generalized across two non-overlapping and well-
powered datasets. As hypothesized, the NbM!EC rela-
tionship was moderated by the presence of abnormal CSF
biomarkers of pTau and amyloid-b, consistent with a
mechanism of trans-synaptic spread of these proteins
across anatomically connected regions. Using whole-brain
regression models, we presented novel evidence that the
relationship between baseline NbM volumes and neurode-
generation was spatially specific to regions of the entorhinal
cortex and the perirhinal cortices. Finally, baseline
Figure 5 NbM and entorhinal cortex predict distinct patterns of downstream degenerative spreading. Baseline volumes of the
NbM and the entorhinal cortex predicting APC in every brain voxel in the pooled abnormal CSF group (aCSF, n = 490). In red, voxels showing a
significant association with baseline volumes in the NbM (A) and in the entorhinal cortex (B) with a P5 0.05 voxel-level FWE-corrected
threshold. Baseline NbM volumes predicted degeneration in the right entorhinal cortex whereas baseline entorhinal cortex volumes predicted
degeneration in regions of the temporal and parietal cortices. Results are rendered into an MNI glass brain to the group DARTEL space using
Mango (http://ric.uthscsa.edu/mango/). Models were tested for significance using non-parametric permutation testing.
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entorhinal cortex volumes predicted neurodegeneration
mainly in regions of the temporal cortex, recapitulating
neurodegenerative spreading dynamics observed in human
in vivo structural imaging work (Dickerson et al., 2001; Du
et al., 2001) and mouse models of trans-synaptic tau
propagation (de Calignon et al., 2012; Liu et al., 2012;
Khan et al., 2014; Wu et al., 2016). These findings high-
light the importance of the cholinergic basal forebrain
nuclei in Alzheimer’s disease and motivate novel interven-
tions targeted to these neuronal populations.
The intrinsic properties of the basal forebrain cholinergic
neurons, including their morphology and propensity for
sustained neuroplasticity throughout adulthood, might be
key to understanding why these cell types are selectively
vulnerable in Alzheimer’s disease (Mesulam, 1999;
Mattson and Magnus, 2006; Saxena and Caroni, 2011;
Wu et al., 2014; Roussarie et al., 2019). The NbM cholin-
ergic neurons have large projecting axons with extensive
arbours that expand long distances in the CNS (Wu
et al., 2014; Li et al., 2018; Yan et al., 2018). Extremely
large axons and arbours exert high metabolic demands in
order to support their maintenance, repair and transport. A
less efficient cellular response to axonal perturbations could
increase their vulnerability to the accumulation of abnor-
mal proteins (Wu et al., 2014). In addition, large surface
areas increase their exposure to toxic environments
(Mattson and Magnus, 2006). Consistent with its selective
vulnerability, the NbM is one of the most vulnerable re-
gions to the early accumulation of intracellular tau path-
ology (Mesulam et al., 2004; Braak and Del Tredici, 2011,
2015) and intraneuronal amyloid oligomers (Baker-Nigh
et al., 2015). There is increasing evidence showing that
intraneuronal amyloid can have deleterious early effects in
neurons, such as disrupting their retrograde axonal trans-
port machinery (Pigino et al., 2009), which in turn can
cause a neurotrophic deficiency (Bellucci et al., 2006) lead-
ing to neurodegeneration (De Lacalle et al., 1996). Recent
functional genomics research examining the molecular pro-
file of different neuronal cell types in the adult brain indi-
cates that those with selective vulnerability to Alzheimer’s
disease, such as the layer II entorhinal neurons, are select-
ively enriched for expression of amyloid precursor protein
(APP) and microtubule-associated protein tau (MAPT)
compared to neurons in primary visual and somatosensory
cortices (Roussarie et al., 2019). Given the hypothesized
physiological roles of APP in synaptic remodelling and
MAPT in microtubule formation, increased neuronal ex-
pression of these genes might represent a heightened pro-
pensity for neuroplasticity in adulthood—consistent with
the known role of entorhinal neurons in memory encoding.
The cholinergic basal forebrain neurons—which constitute
the primary source of acetylcholine for the entire brain—
are thought to exhibit a similar propensity for adult neu-
roplasticity due to their role in learning and memory
(Mesulam, 1999). Cholinergic neuromodulation is essential
for triggering entorhinal and hippocampal plasticity during
encoding of novel sensory information (Sarter et al., 2003;
Hasselmo, 2006; Botly and De Rosa, 2009; Heys et al.,
2010; Gu and Yakel, 2011; Mitsushima et al., 2013;
Schmitz and Duncan, 2018). Whether APP and MAPT ex-
pression is similarly elevated in cholinergic basal forebrain
remains to be determined. Nevertheless, the cholinergic
basal forebrain neurons exhibit a unique mixture of mor-
phological and functional properties which appear to
heighten their vulnerability to structural degeneration in
the ageing brain.
In this study, the pathological spread of neurodegenera-
tion from the NbM to the entorhinal cortex was exacer-
bated in individuals with abnormal levels of CSF pTau and
amyloid-b. Evidence from non-human animal studies shows
that protein aggregates can spread trans-synaptically to
neuroanatomically connected regions. In an APP mouse
model of Alzheimer’s disease, neuronal accumulation of
amyloid-b was observed first in the entorhinal cortex, fol-
lowed by the dentate gyrus, a downstream region receiving
monosynaptic projections from the entorhinal cortex
(Harris et al., 2010). Evidence further suggests that tau
aggregates propagate from the entorhinal cortex to limbic
and then neocortical connected areas (de Calignon et al.,
2012; Liu et al., 2012; Walker et al., 2013; Khan et al.,
2014; Wu et al., 2016). For example, in mice that ex-
pressed human tau restricted to the entorhinal cortex, the
axonal terminals of the entorhinal cortex projecting neu-
rons showed increasing markers of tauopathy over time
(Liu et al., 2012). In all, this shows that amyloid-b and
pTau can propagate synaptically across neural networks
of anatomically connected vulnerable cells. If the NbM is
one of the earliest regions to accumulate tau and amyloid-
b, then these proteins may spread to the entorhinal cortex
trans-synaptically, inducing the observed downstream neu-
rodegeneration. Our results are therefore compatible with
animal research showing a trans-synaptic mechanism of
abnormal spreading of tau proteins. However, to ultimately
demonstrate that degeneration in the entorhinal cortex is
driven by the spread of tau pathology from the NbM in
humans, longitudinal studies integrating both structural
MRI and tau PET are needed. In addition, we observed a
relationship between the NbM!EC in the normal CSF
group. This effect was weaker and not reliable across sam-
ples, indicating the possibility that there are other age-
related pressures on the NbM cholinergic neurons inde-
pendent from amyloid-b and pTau (Wurtman et al.,
1990; Nitsch et al., 1992; Wurtman, 1992). Nevertheless,
we found that the presence of abnormal amyloid-b and
pTau was the strongest moderating factor on the relation-
ship between NbM!EC; this relationship was robust to
differences in APOE genotype, clinical diagnosis and
ADNI cohort (magnetic resonance field strength).
Collectively, our findings indicate that degeneration of the
NbM and entorhinal cortex pathway is likely influenced by
multiple genetic and environmental risk factors which may
disrupt amyloid and tau proteostasis in the ageing brain,
such as vascular health (Iturria-Medina et al., 2016).
Additional modelling of these complex multivariate changes
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will be necessary to unravel the age-related factors that
most reliably predict abnormal accumulation of amyloid
and tau.
Our study extends on prior in vivo structural MRI stu-
dies demonstrating pronounced basal forebrain degener-
ation in the context of ageing and Alzheimer’s disease.
For instance, in prior work, reduced basal forebrain vol-
umes have been observed in MCI patients both cross-sec-
tionally (Teipel et al., 2005, 2011, 2017; Grothe et al.,
2010, 2012; Kilimann et al., 2014, 2017; Cantero et al.,
2017) and longitudinally (Grothe et al., 2013; Schmitz and
Spreng, 2016; Cavedo et al., 2017; Schmitz et al., 2018).
Here we used a novel combination of CSF biomarkers,
longitudinal structural MRI, a large replication sample
and regression-based whole-brain modelling to demonstrate
a reliable (Fig. 3A–E) and highly specific (Fig. 5A) sequence
of neurodegeneration from the NbM to the entorhinal
cortex. Our evidence in favour of the NbM!EC model
accords with numerous post-mortem histology studies
implicating the selective vulnerability of NbM cholinergic
cell populations (Davies and Maloney, 1976; Whitehouse
et al., 1981; Arendt et al., 1985, 2015; Mesulam et al.,
2004; Geula et al., 2008; Braak and Del Tredici, 2011,
2015; Braak et al., 2011; Baker-Nigh et al., 2015; Hanna
Al-Shaikh et al., 2019). However, predictive staging based
on histological strategies are limited by the heterogeneity of
the post-mortem samples, the inability to track pathology
with progressive neurodegeneration within individuals, the
variability in tissue staining techniques used to profile
underlying pathology, and the variability in anatomical
coverage across both cortical and subcortical regions. We
overcame these limitations by using an in vivo longitudinal
neuroimaging strategy of predictive pathological staging in
a large cohort of 4800 older adults. We quantified the
baseline CSF profile of amyloid-b and pTau in each indi-
vidual based on the automated Elecsys protocol, which
was harmonized between samples. We then applied an in-
dependently defined cut-off point to delineate unbiased
groups of individuals exhibiting abnormal and normal
CSF biomarkers. By comparing the spreading dynamics of
neurodegeneration between these two groups, we demon-
strated that baseline NbM volumes predicted an accelerated
annual rate of degeneration in a future time point in the
entorhinal cortex. Although this effect was strongest in the
right hemisphere entorhinal cortex, additional predictive
effects in the left hemisphere entorhinal cortex were detect-
able at a more liberal uncorrected threshold. It is currently
unknown whether hemispheric asymmetries exist in the vul-
nerability of the NbM!EC pathway, nor what risk factors
would influence such asymmetry. Finally, we found evi-
dence that this neuropathological background was asso-
ciated with neurodegenerative spreading from entorhinal
cortex to targets of its projections in the medial temporal
lobes. These latter findings parallel those of recent cross-
species translational research comparing transgenic mouse
models of Alzheimer’s disease with at-risk human partici-
pants (Khan et al., 2014). In all, our results demonstrate
that NbM degeneration is an earlier pathological event in
the Alzheimer’s disease pathological cascade.
Although support for the NbM!EC model reliably gen-
eralized between two different populations, we cannot infer
from this finding whether the NbM is the origin of
Alzheimer’s disease pathophysiology. Based on post-
mortem histological analyses, other ascending neuromodu-
latory cell populations have been found to exhibit early
degeneration in ageing, MCI and Alzheimer’s disease. In
particular, post-mortem histology work has repeatedly
identified severe tau accumulation and neuronal cell loss
in the cluster of noradrenergic brainstem neurons known
as the locus coeruleus (Zarow et al., 2003; Heneka et al.,
2006, 2010; Grudzien et al., 2007; Braak and Del Tredici,
2011, 2015; Braak et al., 2011; Arendt et al., 2015; Ghosh
et al., 2019). Like neurons of the cholinergic basal fore-
brain and layer II entorhinal cortex, the locus coeruleus
norandrenergic neurons have large complex axonal projec-
tions (Schwarz and Luo, 2015; Schwarz et al., 2015),
which may account in part for their apparent selective vul-
nerability to early degeneration. The T1-weighted structural
MRI data used in this study are poorly optimized for quan-
tifying grey matter volume in brainstem nuclei such as the
locus coeruleus (Lambert et al., 2013a, b). Nevertheless,
stereotactic probabilistic atlases of the human locus coeru-
leus are available (Keren et al., 2009; Tona et al., 2017)
and novel magnetic resonance sequences optimized for
quantifying the brainstem volume in vivo are under devel-
opment (Lambert et al., 2013a, b). Future work examining
anatomically comprehensive staging models of Alzheimer’s
disease pathophysiology would therefore benefit by inte-
grating these magnetic resonance sequences into their scan
acquisition protocols.
To understand the predictive staging of basal forebrain
neurodegeneration at even earlier stages of Alzheimer’s dis-
ease, another necessary step will involve parallel in vivo
quantification of longitudinal changes in both the grey
and white matter microstructure. Diffusion-weighted MRI
techniques enable tractography-based analysis of the basal
forebrain white matter projections (Kerbler et al., 2013;
Ray et al., 2015). PET, combined with radiotracers that
selectively bind to the vesicular acetylcholine transporter
(VAChT), a glycoprotein located on presynaptic cholinergic
terminals, represents another promising tool for quantifying
the integrity of the cholinergic basal forebrain projectome
in vivo (Aghourian et al., 2017; Schmitz et al., 2018).
Because degeneration of the cholinergic cell body in the
NbM is likely preceded by a period of distal axonal degen-
eration (Yan et al., 2018), these neuroimaging techniques
might provide insight into even earlier stages of Alzheimer’s
disease pathophysiology. For instance, spatially selective
genetic knock-down of VAChT in the mouse hippocampus
was found to alter RNA metabolism and induce
Alzheimer’s disease-like changes in proteostasis (Kolisnyk
et al., 2016), suggesting that loss of cortical cholinergic
input is by itself sufficient to induce pathophysiology.
Whether age-related cortical cholinergic denervation
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induces similar pathophysiology in the human brain re-
mains to be determined.
Finally, we note that because ADNI is a multi-site study,
MRI data were acquired in multiple different scanners,
which might introduce variability in the quality of the
images used to quantify grey matter volume. Despite sig-
nificant efforts to harmonize the acquisition and postpro-
cessing phases of neuroimaging data (Jack et al., 2008),
non-biological variations between scanners may impact
the volumetric estimations from T1 images (Jovicich et al.,
2009; Kruggel et al., 2010). However, studies using struc-
tural MRI to examine Alzheimer’s disease neurodegenera-
tion do not show an interaction between scanner and
diagnosis and a smaller effect of scanner than of diagnostic
group in grey matter regions (Stonnington et al., 2008). In
the present study, we calculated annualized per cent rates
to evaluate grey matter changes over time. Presumably,
calculating a difference between successive time points
would minimize the influence of variation in global inten-
sity caused by interscanner differences. In addition, our
main regression results (Fig. 3E and J) were robust to the
inclusion of the different sites (scanners) as a fixed-effect
covariate and the distribution of abnormal and normal CSF
participants was comparable across sites (data not shown).
Although it is challenging to perfectly systematize large
multicentre studies, we believe efforts such as ADNI are
currently the best resources available for in vivo staging
of Alzheimer’s disease progression.
In conclusion, the current study provides reliable and
anatomically specific support for a predictive pathological
staging model of Alzheimer’s disease that progresses in
the following sequence: NbM!EC!Neocortex. In all,
our findings call into question a prevailing view of
Alzheimer’s disease pathogenesis, suggesting instead that
degeneration of the basal forebrain cholinergic projection
system is an upstream event to that of its most vulnerable
cortical targets in the entorhinal cortex. If the cholinergic
neurons of the basal forebrain are selectively vulnerable to
the early accumulation and propagation of Alzheimer’s dis-
ease pathology, then interventions targeting these neuronal
populations in early disease stages may be useful for mod-
ifying disease progression prior to cognitive decline.
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